Barbara Osborne to Immunotherapy
This is a "connection" page, showing publications Barbara Osborne has written about Immunotherapy.
Connection Strength
0.258
-
Sierra RA, Trillo-Tinoco J, Mohamed E, Yu L, Achyut BR, Arbab A, Bradford JW, Osborne BA, Miele L, Rodriguez PC. Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance. Cancer Res. 2017 10 15; 77(20):5628-5638.
Score: 0.115
-
Monticone G, Huang Z, Csibi F, Leit S, Ciccone D, Champhekar AS, Austin JE, Ucar DA, Hossain F, Ibba SV, Boulares AH, Carpino N, Xu K, Majumder S, Osborne BA, Loh C, Miele L. Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses. Front Immunol. 2022; 13:987298.
Score: 0.041
-
Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021 02; 20(2):125-144.
Score: 0.036
-
Nguyen A, Ramesh A, Kumar S, Nandi D, Brouillard A, Wells A, Pobezinsky L, Osborne B, Kulkarni AA. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci Adv. 2020 10; 6(40).
Score: 0.036
-
Hossain F, Majumder S, Ucar DA, Rodriguez PC, Golde TE, Minter LM, Osborne BA, Miele L. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Front Immunol. 2018; 9:1288.
Score: 0.030